Ladetto, M
Ferrero, S
Drandi, D
Festuccia, M
Patriarca, F
Mordini, N
Cena, S
Benedetto, R
Guarona, G
Ferrando, F
Brunello, L
Ghione, P
Boccasavia, V
Fanin, R
Omedè, P
Giaccone, L
Palumbo, A
Passera, R
Boccadoro, M
Bruno, B
Article History
First Online: 6 October 2015
Competing interests
: AP has received consultancy and honoraria from Amgen, Bristol-Myers Squibb, Celgene, Janssen, Millenium, Onyx; MB has received research support, consultancy and scientific advisory board for Celgene and Janssen-Cilag; ML has received research support from Janssen-Cilag, Amgen, Roche and Italfarmaco, and honoraria from Celgene, Roche, Bayer, Amgen and Mundipharma; SF has received speakers honoraria from Celgene and Mundipharma; BB has received honoraria from Gilead, Pfizer, Celgene, Hospira and research support form Celgene, Pierre Fabre, ADIENNE, Hospira Italia, MSD Italia. FP has received honararia from Celgene, Janssen, MSD Italia; Advisory Board for Mundipharma, Bristol MSD, Janssen. The remaining authors declare no conflict of interest.